Survival benefits of postoperative adjuvant chemotherapy in adults aged ≥ 80 years with locally advanced gastric cancer: insights from a population-based study
Postoperative adjuvant chemotherapy should be considered for patients aged ≥ 80 years with LAGC, especially those with lymph node involvement, as it offers significant survival benefits. However, as age approaches 90 years, the benefits of adjuvant chemotherapy may diminish, warranting more cautious application.
Authors
- Wu Guoju
- Jian Cui (ORCID: https://orcid.org/0000-0002-3885-6782)
- Xianglong Cao
- Tianming Ma (ORCID: https://orcid.org/0000-0001-6045-3130)
- Jianxin Shi (ORCID: https://orcid.org/0000-0002-6481-0032)
- Zijian Li (ORCID: https://orcid.org/0000-0002-8057-2257)
- Qi An (ORCID: https://orcid.org/0000-0001-5479-9493)
- Tao Yu (ORCID: https://orcid.org/0000-0001-9345-3890)
- Gang Zhao (ORCID: https://orcid.org/0000-0002-1404-1626)
- Jinghai Song (ORCID: https://orcid.org/0000-0002-7101-8000)
- Fuhai Ma (ORCID: https://orcid.org/0000-0003-2437-6881)
- Yangyang Zheng (ORCID: https://orcid.org/0009-0004-3826-4586)
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
Publication Details
- Journal
- Discover Oncology
- Published
- 2025-05-01
- DOI
- https://doi.org/10.1007/s12672-025-02375-9
- Citations
- 1
- Primary Topic
- Gastric Cancer Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 1.52